Major Research Direction of the Team:
1. Early screening and clinical precise treatment of malignant tumors
2. Screening, identification and functional research of innovative anti-tumor drug targets
3. Research on the material basis and molecular mechanism of anti-tumor active ingredients derived from traditional Chinese medicine
Major Scientific Research Projects Undertaken by the Team:
1. Confirmation of a New KRAS-MEK1 Nuclear Translocation-YAP Pathway and Its Significance in Direct Targeted Mutant KRAS Molecular Therapy for Intestinal Cancer, General Program of National Natural Science Foundation of China, 2019-2022, RMB 570,000.
2. Receptor Expression and Signal Transduction Mechanism of Disease-Related Brain Regions in Medical Imaging, Innovation Research Group Project of National Natural Science Foundation of China, 2017-2022, RMB 1.55 million.
3. Early Warning and Diagnosis of Colorectal Cancer, Clinical Verification of Markers for Curative Effect and Prognosis Judgment, Key Special Project of the National Key Research and Development Program, 2017-2020, RMB 1.35 million.
4. Research on the Mechanism of DNA Polymerase Zeta (Pol Zeta) Maintaining Genome Stability, Youth Program of National Natural Science Foundation of China, 2016-2018, RMB 240,000.
5. Effect of CtBP1 Transcription Regulation DNA Damage Repair Signal Pathway on Malignant Phenotype and Drug Resistance of Tumor, Youth Program of National Natural Science Foundation of China, 2017-2019, RMB 200,000.
Core Research Achievements of the Team:
1. Xu H, Zhou S, Xia H, Yu H, Tang Q, Bi F*.MEK nuclear localization promotes YAP stability via sequestering β-TrCP in KRAS mutant cancer cells. Cell Death Differ.2019. (SCI-JCR Zone 1, IF:10.72)
2. Dai X, Xia H, Zhou S, Tang Q, Bi F*.Zoledronic Acid Enhances the Efficacy of the MEK Inhibitor Trametinib in KRAS Mutant Cancers. Cancer Lett. 2019, 442(1): 202-212. (SCI-JCR Zone 1, IF:7.36)
3. Li, J, Li W, Huang K, Zhang Y, Kupfer G, Zhao Q*. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. J Hematol Oncol,2018,11:1-18. (SCI-JCR Zone 1, IF:11.06)
4. Zhou S, Xia H, Xu HJ, Tang QL, Bi F*. ERRα suppression enhances the cytotoxicity of the MEK inhibitor trametinib against colon cancer cells. J Exp Clin Cancer Res. 2018,37(1): 218. (SCI-JCR Zone 2, IF:7.07)
5. Formation Mechanism of "Chronic and Refractory" Skin Ulcer and Intervention Strategy of "Clearing Heat, Removing Blood Stasis and Tonifying Deficiency" of Traditional Chinese Medicine, Deng Yu, 2018, the Second Prize of Shanghai Science and Technology Progress Award
